TTC3

Across TCGA pan-cancer cohorts, TTC3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TTC3 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher TTC3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TTC3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

SCLC, UCEC, and SKCM are the cancer types where TTC3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	All	0.110	0.633	<.001	36	view →
UCEC	DFS	Median	All	0.938	0.608	.002	30	view →
SKCM	OS	Median	All	0.679	0.793	.008	11	view →
STAD	DFS	Median	All	0.130	0.508	.014	9	view →
BLCA	OS	Median	III,IV	0.756	0.340	.016	8	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TTC3–SCLC (DFS)

Open the SCLC breakdown →